Personalis Stock

Personalis Equity

The The Equity of Personalis (PSNL) as of Aug 16, 2026 is 261.19 M USD. In the previous year, The Equity was 202.96 M USD — a change of 28.69% (higher).

Equity

261.19 MUSD

YoY

28.69%

Last updated:

In 2026, Personalis's equity was 261.19 M USD, a 28.69% increase from the 202.96 M USD equity in the previous year.

Access this data via the Eulerpool API

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Personalis's Equity

Personalis's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Personalis's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Personalis's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Personalis's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Personalis’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Personalis stock

The Equity of Personalis is 261.19 M USD in 2026.

The Equity of Personalis changed from 202.96 M USD to 261.19 M USD, representing a 28.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Personalis since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Personalis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Personalis

All Key Metrics — Personalis